Female Reproductive Aging & Menopause

Terminology & Phases

• Menopause
– Definition = a woman’s final menstrual period (FMP) caused by exhaustion of ovarian follicles.
– Identified retrospectively: diagnosed after $1$ year of amenorrhoea with no other cause.
– Median Australian age ≈ $51$ years (global middle $49!–!54$ ).

• Post-menopause
– Life stage after the FMP.

• Perimenopause / Menopausal Transition
– Begins when biological changes & symptoms start before FMP and continues $\sim4!–!6$ years after.
– Characterised by irregular cycle length (short/long, unpredictable).
– Popular speech often calls this whole period “going through menopause”.

• Premature Menopause
– Menopause < $40$ years.
– Causes that accelerate follicle depletion:
• Bilateral oophorectomy (surgical removal of ovaries)
• Chemotherapy / pelvic radiation
• Heavy cigarette smoking (advances age at menopause by ≈ $1$ year)

• NOT causative / myths
– Age at menarche, number of pregnancies, oral-contraceptive use, or ovulation induction with fertility drugs do NOT delay or hasten menopause; continuous follicular recruitment & atresia persist regardless of ovulation status.

Timing & Population Data

• $50\%$ of women experience menopause between $49$ and $54$ years.
• Timing strikingly constant across eras & ethnicities ⇒ argues against mere senescent decay.

Evolutionary Perspectives

• Life-history puzzle: humans live $\approx30\%$ of life after fertility (to $82!–!83$ yrs; even $100$ gives $\sim50\%$ post-fertile).
• Rejected explanations
– “Artifact of modern longevity” contradicted by ancient references (e.g., Greeks placed cessation ~ $50$ yrs) & archaeological evidence of potential long life.
– Senescence hypothesis fails because other organ systems show wide variance; menopause does not.

• Adaptive hypotheses
– Mothering hypothesis: older mothers face higher obstetric risk; ceasing reproduction protects existing children.
– Grandmother hypothesis: post-fertile women enhance inclusive fitness by aiding survival & reproduction of grandchildren; better explains longevity to >60!–!65 yrs.

Biology of Follicle Depletion

• Ovarian follicle pool peaks mid-gestation: $\sim7!–!8\times10^6$ ; declines relentlessly.
• Key checkpoints
– Birth ≈ $2{,}000{,}000$
– Puberty ≈ $400{,}000$
– Accelerated loss after $35!–!37$ yrs when pool falls below $25{,}000$ .
– Menopausal transition begins when only $\sim200$ follicles remain.
– At menopause → $\approx0$ functional follicles.

• Animal data: experimentally lowering oocyte number speeds further loss ⇒ supports “threshold” effect.

Endocrine Cascade of the Transition

Decline in Inhibin B (granulosa-cell product) – earliest hormonal marker.
– In $41\%$ of perimenopausal women, levels fall below assay detection.
FSH rises (negative feedback removed).
Estradiol (E2) initially maintained/high by FSH-driven follicular rescue.
– Hypothalamus/pituitary desensitise to E2 → LH surge fails → ↑ anovulatory cycles → irregular bleeding.
Late transition: follicle exhaustion ⇒ sharp drop in E2; ovaries cease progesterone & inhibin production.
Post-menopause: Estrogen source shifts to peripheral aromatisation of adrenal/ovarian stromal androgens; main circulating form = estrone (E1) – weaker receptor affinity → limited physiological protection.

Symptomatology & Pathophysiology

• Irregular Menses – alternating anovulatory/ovulatory cycles.

• Urogenital Atrophy
– ↓ collagen & vascularity in vaginal wall; thinning, loss of elasticity.
– ↓ cervical secretions → vaginal dryness.
– Vaginal pH rises (loss of glycogen → ↓ lactic acid) ⇒ ↑ UTI & vaginitis.

• Skin & Hair
– ↓ cutaneous collagen → wrinkling, fragility.
– Androgen : estrogen ratio shifts → possible facial hirsutism.

• Skeletal
– E2 normally inhibits osteoclasts & favours osteoblasts.
– Post-E2 drop ⇒ ↑ bone resorption → osteoporosis risk.

• Cardiovascular
– Premenopausal E2 lowers LDL & raises HDL.
– Protection lost post-menopause; CV risk rises.

• Vasomotor Symptoms (Hot Flushes/Flashes)
– Prevalence $50!–!75\%$ in Australian/Western women; start $\sim2$ yrs before FMP.
– Phenomenology: sudden heat over face/neck/chest, skin vasodilation, sweating, transient core temp drop.
– Also common in men on androgen-deprivation therapy.
– Cultural variation: far lower reports in Japanese/Chinese women – hypotheses:
• Diet rich in phyto-oestrogens (soy).
• More positive cultural framing of ageing.
– Triggers/modifiers: smoking, younger menopausal age, temperature transitions.
– Mechanism (leading hypothesis): loss of E2 destabilises hypothalamic thermoregulatory set-point → exaggerated heat-dissipation response to minimal stimuli.

• Psychosomatic / Cognitive
– Insomnia (night sweats), mood swings, anxiety, depression.
– May stem from physical discomfort and direct E2 effects on brain.

• Symptom resolution
– Typically wane within few years post-FMP.
– Hypothesis: body acclimatises to new low-steroid baseline; relative rather than absolute E2 drop drives symptoms.

Management Strategies

• Lifestyle / Non-pharmacological
– Regular exercise, weight-bearing activity, adequate calcium & vitamin D.
– Limit alcohol/caffeine, stop smoking, identify hot-flush triggers.
– Stress-reduction, CBT, meditation for mood & sleep.
– Dietary phyto-oestrogens (soy, flaxseed) – mixed evidence.

• Hormone Therapy (HT / HRT)
– Goal: replace oestrogen ± progestin to relieve E2-deficit sequelae.
– Regimen choices:
• Unopposed E2 → only in women without uterus (post-hysterectomy).
• E2 + progestin for women with uterus to prevent endometrial hyperplasia/cancer.
– Delivery methods: oral tablets, transdermal patches/gels, vaginal creams/rings, nasal spray, implants, intra-uterine progestin devices.

• Other Pharmacotherapies
– SERMs (e.g., raloxifene): estrogen agonist/antagonist properties varying by tissue.
– Bisphosphonates for osteoporosis.
– SSRIs/SNRIs, gabapentin, clonidine for vasomotor & mood symptoms.

Benefits & Risks of Hormone Therapy

• Demonstrated Benefits
– ~ $90\%$ reduction in vasomotor symptoms.
– Improves vaginal atrophy, sexual function, sleep, mood.
– ↑ Bone mineral density; ↓ vertebral & hip fractures when started early with lifestyle co-measures.
– Cognitive: early-start HT linked to ↓ Alzheimer’s risk (↓ β-amyloid, ↑ neuronal growth & cerebral perfusion).
– Favourable lipid profile (↑ HDL, ↓ LDL) – potential cardioprotection (evidence mixed).

• Risks (relative increases; absolute baseline risk is low in 50-yr-old women)
– Stroke: + $46\%$ after $\ge3$ yrs.
– Venous thrombo-embolism (VTE) & coronary events: $+4.2$ -fold after $1$ yr; baseline $8/10{,}000$ → $19/10{,}000$ .
– Breast cancer: + $26\%$ after $\ge4$ yrs combined E2+progestin (most women discontinue earlier).

• Decision-making
– Must individualise: balance symptom burden vs. personal/family risk factors (breast Ca, CVD, clotting disorders).
– Lowest effective dose, shortest duration aligning with treatment goals.

Summary Cheat-Sheet

• Menopause = final period; timing tightly clustered around $51$ yrs.
• Trigger = follicle exhaustion → inhibitory hormone loss (Inhibin B ↓) → FSH ↑ → eventual E2 ↓.
• Symptoms stem chiefly from oestrogen deficiency and include vasomotor, urogenital, skeletal, CV, and mood/cognitive effects.
• Evolutionary theories (mothering, grandmother) suggest adaptive value.
• Hot flushes (50–75 %) arise from hypothalamic set-point instability; culturally modulated.
• First-line management ranges from lifestyle tweaks to systemic HT; HT highly efficacious but carries small absolute vascular & neoplastic risks → personalised assessment essential.
• Symptoms usually abate within a few years; long-term focus shifts to bone and cardiovascular health maintenance.